As per MRFR analysis, the South America Geographic Atrophy GA Market Size was estimated at 1.08 (USD Billion) in 2024.The South America Geographic Atrophy GA Market Industry is expected to grow from 1.11(USD Billion) in 2025 to 2.24 (USD Billion) by 2035. The South America Geographic Atrophy GA Market CAGR (growth rate) is expected to be around 6.579% during the forecast period (2025 - 2035).
In South America, the Geographic Atrophy (GA) market is experiencing significant developments driven by an aging population and increasing awareness of age-related macular degeneration. With life expectancy rising in countries like Brazil and Argentina, the prevalence of GA is also growing, urging healthcare providers to prioritize research and treatment options. The demand for innovative therapies is further catalyzed by advancements in technology and increased focus on ophthalmology research, aiming to provide better diagnostic tools and treatment solutions. times have observed a surge in collaborations among pharmaceutical firms and research institutions in South America.
This trend is notable in countries like Chile and Colombia, where clinical trials are gaining pace, allowing for a quicker understanding of GA treatment efficacy. Telemedicine and digital health solutions are finding a foothold in the South American healthcare landscape, offering remote access to specialists and facilitating early diagnosis and intervention for at-risk patients. Despite challenges, there are opportunities to be explored in the South American GA market. The incorporation of artificial intelligence in diagnosing eye diseases represents a promising frontier, enhancing precision and patient outcomes. Moreover, new policies aimed at improving healthcare access, particularly in rural areas, could facilitate better treatment for GA patients.Overall, with the combination of rising public health initiatives and technological innovations, the South American Geographic Atrophy market shows substantial potential for growth and improvement in patient care.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Growing Aging Population Driving Increased Demand
The South America Geographic Atrophy GA Market Industry is expected to see accelerated growth due to an increasing aging population. According to data from the United Nations, the population aged 60 years and older in South America is projected to increase by approximately 25% in the next decade. This demographic trend is particularly pronounced in countries like Brazil and Argentina, which host significant portions of the elderly . The World Health Organization has highlighted that age-related eye diseases, including geographic atrophy, are becoming more prevalent with the aging population.
As healthcare systems adapt, the demand for specialized treatments and interventions in geographic atrophy will further increase, especially with established organizations like the Brazilian Society of Ophthalmology focusing on awareness and treatment of age-related macular degeneration. This driver reaffirms the necessity for investments in the South America Geographic Atrophy GA Market, as stakeholders work to address the growing needs of this demographic.
Advancements in Research and Development
Significant advancements in Research and Development (R&D) related to geographic atrophy treatments are fostering growth in the South America Geographic Atrophy GA Market Industry. The Latin American Council of Ophthalmology, along with other medical institutions, is prioritizing innovative solutions for managing geographic atrophy, leading to numerous clinical trials in the region. Data from the National Agency for Health Surveillance in Brazil indicates that there has been a 30% increase in research initiatives related to eye health in the past five years.This increase is critical as new therapies continue to emerge, paving the way for better patient outcomes and consequently increasing market potential. The involvement of major pharmaceutical companies in local partnerships also signals a commitment to addressing geographic atrophy issues, ensuring that research flows into practical treatment options.
Increasing Awareness and Diagnosis of Eye Diseases
There is a growing awareness about eye diseases, particularly geographic atrophy, in South America, which is significantly affecting the South America Geographic Atrophy GA Market Industry. A recent campaign organized by the Argentine Society of Ophthalmology has highlighted the importance of early detection and treatment for diseases linked to age-related vision decline. Their findings showed that roughly 40% of individuals aged above 50 are unaware of the risk factors associated with geographic atrophy.With the deployment of community outreach programs and educational initiatives, there is greater public awareness, which is likely to increase the number of patients seeking diagnosis and treatment, and, in turn, foster market growth. Efforts by health care providers in collaboration with non-governmental organizations help disseminate information, which aids in the construction of this favorable outlook.
The Age Group segmentation within the South America Geographic Atrophy GA Market reveals critical insights into the demographic trends shaping this sector. The population aged above 60 years is steadily increasing in South America, primarily due to longer life expectancies and improved healthcare systems, particularly in countries such as Brazil, Argentina, and Chile. This age group is extremely significant, as they tend to exhibit higher rates of geographic atrophy, making them a primary focus for the industry. As the population continues to age, there is an escalating demand for medical treatments aimed at mitigating the effects of age-related vision loss, highlighting the need for innovative therapies and supportive measures.
In the Age Group of Above 75 years, the significance further amplifies due to the heightened prevalence of age-related conditions, including macular degeneration, which directly impacts vision quality. This demographic represents a vital part of the South America Geographic Atrophy GA Market as they typically require more intensive medical management and care options. Healthcare policies in South America are increasingly addressing the requirements for this elderly population, thus presenting valuable opportunities for stakeholders in the market aiming to cater to their needs.
The growing awareness of geographic atrophy and its implications among healthcare providers and patients alike is also contributing to the market's expansion. Moreover, advancements in research and development are yielding promising outcomes, fostering a collaborative effort between various entities to improve treatment strategies and enhance patient outcomes.
Overall, the Age Group segmentation indicates a clear focus on older adults as a critical market segment, emphasizing a collective responsibility towards developing effective healthcare solutions for the elderly population facing geographic atrophy and related issues in South America.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Diagnosis segment of the South America Geographic Atrophy GA Market plays a crucial role in the effective identification and assessment of geographic atrophy, a leading cause of vision loss. With a market poised for significant growth, the focus on advanced diagnostic technologies is becoming essential. Fundus Autofluorescence is critical as it provides detailed imaging of retinal tissues, enabling early detection of changes, which is vital for timely intervention. Similarly, Optical Coherence Tomography Angiography offers non-invasive imaging that enhances the visualization of retinal vascular structure, thus offering invaluable insights for clinical decision-making.
Multifocal Electroretinography complements these techniques by assessing retinal function across various regions, providing a comprehensive evaluation that supports more tailored treatment strategies. As the South American population ages, increased prevalence of age-related macular degeneration necessitates the widespread adoption of these advanced diagnostic tools. The combination of these techniques represents a holistic approach to managing geographic atrophy, presenting opportunities for healthcare providers to enhance patient outcomes in this region.The South America Geographic Atrophy GA Market is characterized by a growing demand for innovative diagnostic solutions that are essential for combating this debilitating condition effectively.
The Therapeutic Agents Clinical Phase segment within the South America Geographic Atrophy GA Market is critical to enhancing treatment options and improving patient outcomes. This segment comprises various stages of drug development, including Late-Stage, Phase II, Phase I, Pre-Clinical Stage, and Discovery Candidates. Late-Stage therapies typically draw significant attention as they are closest to entering the market, holding promise for effective interventions. Meanwhile, Phase II trials focus on expanding understanding of treatment efficacy and safety, becoming essential for subsequent regulatory approvals.
Phase I trials initiate safety testing in a small group of individuals, laying the foundation for further development. The Pre-Clinical Stage is vital in identifying potential therapeutic candidates before human trials, while Discovery Candidates represent innovative approaches to treatment that could reshape management of Geographic Atrophy. The South America region, with its aging population and rising prevalence of eye-related diseases, presents substantial opportunities for growth in these clinical phases, fueled by a combination of academic research, emerging biotech companies, and increasing investment in Research and Development.These dynamics collectively reflect the critical importance of the Therapeutic Agents Clinical Phase segment, positioning it as a key driver of progress in the management of Geographic Atrophy in South America.
The South America Geographic Atrophy GA Market is characterized by diverse regional dynamics that significantly contribute to market growth and segmentation. Brazil stands out as a significant player in this market due to its large population and high incidence of age-related macular degeneration, which drives demand for treatment options. Mexico also plays a crucial role with its expanding healthcare infrastructure and rising awareness about vision health, making it a growing market for Geographic Atrophy solutions. Argentina, with its increasing healthcare investment, is seeing enhanced access to advanced treatment methods, thus contributing to the overall market expansion.The Rest of South America is noteworthy, as it encompasses various countries that are gradually increasing health expenditures and adopting innovative therapies.
The combination of an aging population, increasing prevalence of chronic eye diseases, and advancements in medical technology are key growth driver across these regions. Furthermore, opportunities arise from the growing collaboration among healthcare providers and pharmaceutical companies to enhance treatment accessibility and affordability in the South America Geographic Atrophy GA Market.Understanding these regional characteristics is essential for stakeholders looking to optimize their strategies and meet the unique needs of the South American population.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The South America Geographic Atrophy GA Market is characterized by a burgeoning landscape driven by an increase in the aging population and a heightened prevalence of retinal diseases, particularly age-related macular degeneration. This market is witnessing intensified competition as various players strive to establish a foothold through innovative treatment options, advanced technologies, and strategic collaborations. The competitive dynamics are shaped by several factors including regulatory harmonization, shifting healthcare policies, and growing awareness among patients and healthcare providers about the significance of early diagnosis and intervention in managing Geographic Atrophy.
Companies are innovating their product pipelines to address unmet medical needs while also focusing on improving patient outcomes, thereby making this region a significant area for investment and growth in the ophthalmological sector.Carl Zeiss AG has significantly established its presence in the South American Geographic Atrophy GA Market through its advanced imaging solutions and diagnostic tools tailored for ophthalmology. The company's strengths lie in its robust R&D capabilities, allowing continuous innovation in visualization and precision measurement technologies that aid in the early detection of retinal conditions, including Geographic Atrophy. Its extensive distribution network in South America fosters a strong market presence, and partnerships with healthcare institutions enhance its credibility and reach.
The company's commitment to training and education for local healthcare practitioners further strengthens its position in the market, enabling better patient management for those suffering from sight-threatening conditions.Eyegate Pharmaceuticals is also a key player in the South American Geographic Atrophy GA Market, particularly known for its novel drug delivery systems and innovative therapies aimed at treating retinal diseases. The company focuses on developing biopharmaceutical products that allow for less invasive treatment options, thereby addressing a critical gap in the current treatment landscape.
Eyegate's strengths lie in its proprietary technologies that promise to enhance drug absorption and efficacy in the ophthalmic domain. The company has been pursuing strategic partnerships and collaborations within South America to expand its market reach and drive the commercial success of its key products. Eyegate's commitment to innovation is underscored by its active engagement in clinical trials and research initiatives designed to bolster its therapeutic offerings, ultimately enhancing patient outcomes in the region.
Key Companies in the South America Geographic Atrophy GA Market Include
In the South America Geographic Atrophy (GA) Market, recent developments indicate a notable increase in Research and Development investments focusing on therapeutic options and diagnostic tools targeted at retinal diseases. Companies such as Novartis and Bayer are making strides with innovative treatment approaches, while Alcon has expanded its product offering in the region to cater to the growing demand for ophthalmic solutions. In September 2023, EyeGate Pharmaceuticals announced an agreement with a South American distributor to enhance the availability of its GA treatments.
Additionally, Kowa Company reported improved market penetration through partnerships with local health authorities in Brazil. Notably, in August 2023, Roche expanded its collaboration with Astellas Pharma, aiming to accelerate the development of new therapies for macular degeneration, thus strengthening their presence in the South American market. The valuation of the Geographic Atrophy market is expected to rise due to increasing patient awareness and government initiatives to support eye health, particularly in Argentina and Chile. Over the past couple of years, significant efforts to increase accessibility to treatments have been observed, contributing positively to the evolving landscape of the Geographic Atrophy market in South America.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.08(USD Billion) |
| MARKET SIZE 2024 | 1.11(USD Billion) |
| MARKET SIZE 2035 | 2.24(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.579% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Carl Zeiss AG, Eyegate Pharmaceuticals, Envisia Therapeutics, Novartis, Hugel, Kowa Company, Bayer, Fitzgerald Industries International, Astellas Pharma, Alder Biopharmaceuticals, Roche, Eyenovia, Regeneron Pharmaceuticals, Alcon |
| SEGMENTS COVERED | Age Group, Diagnosis, Therapeutic Agents Clinical Phase, Regional |
| KEY MARKET OPPORTUNITIES | Rising elderly population, Increasing awareness programs, Growing prevalence of diabetes, Expanding telemedicine services, Development of novel therapies |
| KEY MARKET DYNAMICS | Increasing elderly population, Rising prevalence of GA, Limited treatment options, Growing awareness initiatives, Advancements in diagnostic technology |
| COUNTRIES COVERED | Brazil, Mexico, Argentina, Rest of South America |
Frequently Asked Questions (FAQ) :
The South America Geographic Atrophy GA Market is expected to be valued at 1.11 USD Billion in 2024.
By 2035, the South America Geographic Atrophy GA Market is anticipated to reach a valuation of 2.24 USD Billion.
The expected CAGR for the South America Geographic Atrophy GA Market during the forecast period from 2025 to 2035 is 6.579%.
Brazil holds the largest market share in the South America Geographic Atrophy GA Market with a valuation of 0.45 USD Billion in 2024.
By 2035, the market size for Argentina in the South America Geographic Atrophy GA Market is projected to reach 0.4 USD Billion.
Key players in the market include major companies such as Novartis, Bayer, and Regeneron Pharmaceuticals.
The market size for individuals above 75 years is expected to be 0.38 USD Billion in 2024.
The Rest of South America region is valued at 0.21 USD Billion in 2024, contributing significantly to the overall market.
Brazil is expected to experience notable market growth with an increase from 0.45 USD Billion in 2024 to 0.91 USD Billion in 2035.
Key growth drivers include an aging population and advancements in treatment options for geographic atrophy.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
